Mirum Pharmaceuticals, Inc., was incorporated in Delaware on May 2, 2018. The Company is a biopharmaceutical company focused on identifying, acquiring, developing and commercializing novel therapies for debilitating rare and orphan diseases. 

Mirum's 15-minute chart has exhibited a narrowing of Bollinger Bands and a bearish Marubozu pattern on September 11th, 2026, at 11:15. This indicates a reduction in the magnitude of stock price fluctuations, suggesting that sellers are in control of the market. Furthermore, the bearish momentum is likely to persist.On September 11, 2026, at 11:15, the 15-minute chart for Mirum displayed a narrowing of Bollinger Bands and a bearish Marubozu candlestick pattern. The contraction of the bands indicates a decrease in price volatility, often signaling <a href="https://www.google.com/goto?url=CAESbwHrOzAVr_RqJvE10Xftc5k0Yxa0OncemxHZdjyTCSMZxHxiWgytnpNNOG8zu0GjBFnQgfaHtOzKSLh6ptigQlePfntAjGn6UK8YB40dyrEX3p_x9xUcJC7CUraA1NW1kj_yHPlOOjHm9m1U2nl6NQ">a period of consolidation</a> or indecision in the market. This tightening can also be interpreted as a precursor to a potential breakout or breakdown, depending on the direction of subsequent price movement.The bearish Marubozu pattern, characterized by a long bearish body with no upper shadow, reinforces the dominance of sellers during the period. This pattern typically suggests <a href="https://www.google.com/goto?url=CAESbwHrOzAVr_RqJvE10Xftc5k0Yxa0OncemxHZdjyTCSMZxHxiWgytnpNNOG8zu0GjBFnQgfaHtOzKSLh6ptigQlePfntAjGn6UK8YB40dyrEX3p_x9xUcJC7CUraA1NW1kj_yHPlOOjHm9m1U2nl6NQ">strong downward momentum</a> and a lack of buying pressure to counter the selling bias. Together, these technical signals imply that bearish sentiment is currently in control and that further downward movement may be likely in the near term.Traders using Bollinger Bands often look for confirmation from other indicators, such as volume or momentum oscillators, to <a href="https://www.google.com/goto?url=CAESbwHrOzAVr_RqJvE10Xftc5k0Yxa0OncemxHZdjyTCSMZxHxiWgytnpNNOG8zu0GjBFnQgfaHtOzKSLh6ptigQlePfntAjGn6UK8YB40dyrEX3p_x9xUcJC7CUraA1NW1kj_yHPlOOjHm9m1U2nl6NQ">validate potential trade setups</a>. In this case, the combination of a narrowing band squeeze and a bearish Marubozu could serve as a cautionary signal for long positions and a potential entry point for short strategies, particularly if volume increases to confirm the bearish bias. Investors are advised to monitor subsequent price action and consider additional technical or fundamental factors before making trading decisions.

Mirum制药

Mirum's 15min chart shows Bollinger Bands Narrowing and Bearish Marubozu.

Mirum's 15-minute chart has recently triggered two significant technical indicators: the MACD Death Cross and the KDJ Death Cross, both of which occurred on September 9th, 2026 at 13:45. These events suggest that the stock price has the potential to continue declining, as the momentum of the stock price is shifting towards the downside and may further decrease.On September 9th, 2026 at 13:45, Mirum Pharmaceuticals (MIRM) triggered two notable technical indicators on its 15-minute chart: the MACD Death Cross and the KDJ Death Cross. These signals suggest a shift in momentum toward the downside, potentially indicating further price declines in the near term. The MACD Death Cross occurs when the MACD line crosses below the signal line, while the KDJ Death Cross is marked by the K line crossing below the D line, both of which are <a href="https://www.google.com/goto?url=CAESawHrOzAVTmnplw_VfNpMUZK3lIpKzhN23LD2iotc0hYlUBMvHM9DXc18fobI0hRZiNlhpFBAS0M9yTdM9VhmBDvKa0meLm1Xgbdc9gzw7s4OACfQkmCloNnS8dlmfBIUfsxgRXSy7pdzRw-p">bearish signals in technical analysis</a>.The death cross pattern, in general, refers to a short-term moving average crossing below a long-term moving average and is often viewed as <a href="https://www.google.com/goto?url=CAESawHrOzAVTmnplw_VfNpMUZK3lIpKzhN23LD2iotc0hYlUBMvHM9DXc18fobI0hRZiNlhpFBAS0M9yTdM9VhmBDvKa0meLm1Xgbdc9gzw7s4OACfQkmCloNnS8dlmfBIUfsxgRXSy7pdzRw-p">a sign of deteriorating price momentum</a>. While it is not a definitive predictor of long-term market outcomes, it is frequently used by traders to gauge short-term sentiment and potential trend reversals. Historical data suggests that <a href="https://www.google.com/goto?url=CAESawHrOzAVTmnplw_VfNpMUZK3lIpKzhN23LD2iotc0hYlUBMvHM9DXc18fobI0hRZiNlhpFBAS0M9yTdM9VhmBDvKa0meLm1Xgbdc9gzw7s4OACfQkmCloNnS8dlmfBIUfsxgRXSy7pdzRw-p">death crosses have occasionally preceded</a> market corrections or bearish phases, though they have also been followed by rebounds in many instances.Investors are advised to monitor Mirum Pharmaceuticals closely in the coming days, as these technical signals may influence short-term trading behavior and market sentiment. As always, technical indicators should be used in conjunction with broader market analysis and fundamental factors to form a comprehensive investment strategy.

Mirum's 15min chart shows MACD Death Cross, KDJ Death Cross.

Mirum Pharmaceuticals has appointed Dr. Rob Myers as Chief Medical Officer, effective September 21, 2026. Dr. Myers has over two decades of experience in developing novel medicines, with a focus on hepatology and primary sclerosing cholangitis. He joins Mirum from OrsoBio, where he served as Chief Medical Officer and Head of Development. Mirum's CEO, Chris Peetz, stated that Dr. Myers' expertise in liver disease and clinical development leadership will be critical in helping the company bring breakthrough medicines forward for people living with rare diseases.

Mirum

Mirum Pharmaceuticals Names Dr. Rob Myers as CMO Effective September 21

Mirum Pharmaceuticals has appointed Dr. Rob Myers as Chief Medical Officer, effective September 21, 2026. Myers has over two decades of experience developing novel medicines, primarily in hepatology and related disorders. He previously held senior leadership positions at Gilead Sciences and OrsoBio, overseeing clinical development programs across liver fibrosis and cholestatic liver diseases. As Chief Medical Officer, Myers will lead Mirum's global medical and clinical development functions.

Mirum Names Dr. Myers as CMO, Effective Sept. 21

Mirum Pharmaceuticals appoints Dr. Rob Myers as chief medical officer

MIRM News